Takeda Begins Japan Trials Of Mood, Anxiety Drugs From Denmark
This article was originally published in PharmAsia News
Takeda Pharmaceuticals says it has begun trials of the first of two drugs licensed from H. Lundbeck of Denmark to treat mood and anxiety disorders. As LuAA21004, the first of the two drugs, enters trials, Takeda plans to develop LuAA24530. The drugs have differing molecular structures and are intended to be sold along side each other. Both drugs are well into Phase II trials in Europe. (Click here for more - a subscription may be required
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.